These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 20501949)
1. The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. Bauman KA; Wettlaufer SH; Okunishi K; Vannella KM; Stoolman JS; Huang SK; Courey AJ; White ES; Hogaboam CM; Simon RH; Toews GB; Sisson TH; Moore BB; Peters-Golden M J Clin Invest; 2010 Jun; 120(6):1950-60. PubMed ID: 20501949 [TBL] [Abstract][Full Text] [Related]
2. Plasminogen-mediated activation and release of hepatocyte growth factor from extracellular matrix. Matsuoka H; Sisson TH; Nishiuma T; Simon RH Am J Respir Cell Mol Biol; 2006 Dec; 35(6):705-13. PubMed ID: 16840775 [TBL] [Abstract][Full Text] [Related]
3. Plasmin overcomes resistance to prostaglandin E2 in fibrotic lung fibroblasts by reorganizing protein kinase A signaling. Okunishi K; Sisson TH; Huang SK; Hogaboam CM; Simon RH; Peters-Golden M J Biol Chem; 2011 Sep; 286(37):32231-43. PubMed ID: 21795691 [TBL] [Abstract][Full Text] [Related]
4. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Swaisgood CM; French EL; Noga C; Simon RH; Ploplis VA Am J Pathol; 2000 Jul; 157(1):177-87. PubMed ID: 10880388 [TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor-1 suppresses profibrotic responses in fibroblasts from fibrotic lungs. Marudamuthu AS; Shetty SK; Bhandary YP; Karandashova S; Thompson M; Sathish V; Florova G; Hogan TB; Pabelick CM; Prakash YS; Tsukasaki Y; Fu J; Ikebe M; Idell S; Shetty S J Biol Chem; 2015 Apr; 290(15):9428-41. PubMed ID: 25648892 [TBL] [Abstract][Full Text] [Related]
6. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. Hattori N; Degen JL; Sisson TH; Liu H; Moore BB; Pandrangi RG; Simon RH; Drew AF J Clin Invest; 2000 Dec; 106(11):1341-50. PubMed ID: 11104787 [TBL] [Abstract][Full Text] [Related]
7. Decreased prostaglandin E2 synthesis by lung fibroblasts isolated from rats with bleomycin-induced lung fibrosis. Ogushi F; Endo T; Tani K; Asada K; Kawano T; Tada H; Maniwa K; Sone S Int J Exp Pathol; 1999 Feb; 80(1):41-9. PubMed ID: 10365086 [TBL] [Abstract][Full Text] [Related]
8. Coordinated induction of cyclooxygenase-2/prostaglandin E2 and hepatocyte growth factor by apoptotic cells prevents lung fibrosis. Yoon YS; Lee YJ; Choi JY; Cho MS; Kang JL J Leukoc Biol; 2013 Nov; 94(5):1037-49. PubMed ID: 23922381 [TBL] [Abstract][Full Text] [Related]
9. Airway remodeling in murine asthma correlates with a defect in PGE2 synthesis by lung fibroblasts. Stumm CL; Wettlaufer SH; Jancar S; Peters-Golden M Am J Physiol Lung Cell Mol Physiol; 2011 Nov; 301(5):L636-44. PubMed ID: 21873451 [TBL] [Abstract][Full Text] [Related]
10. GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandin-dependent mechanism. Moore BB; Coffey MJ; Christensen P; Sitterding S; Ngan R; Wilke CA; McDonald R; Phare SM; Peters-Golden M; Paine R; Toews GB J Immunol; 2000 Oct; 165(7):4032-9. PubMed ID: 11034414 [TBL] [Abstract][Full Text] [Related]
11. Crystalline and amorphous silica differentially regulate the cyclooxygenase-prostaglandin pathway in pulmonary fibroblasts: implications for pulmonary fibrosis. O'Reilly KM; Phipps RP; Thatcher TH; Graf BA; Van Kirk J; Sime PJ Am J Physiol Lung Cell Mol Physiol; 2005 Jun; 288(6):L1010-6. PubMed ID: 15665045 [TBL] [Abstract][Full Text] [Related]
12. The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism. Hattori N; Mizuno S; Yoshida Y; Chin K; Mishima M; Sisson TH; Simon RH; Nakamura T; Miyake M Am J Pathol; 2004 Mar; 164(3):1091-8. PubMed ID: 14982862 [TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor-1 promotes the proliferation and inhibits the apoptosis of pulmonary fibroblasts by Ca(2+) signaling. Zhang YP; Wang WL; Liu J; Li WB; Bai LL; Yuan YD; Song SX Thromb Res; 2013 Jan; 131(1):64-71. PubMed ID: 23021499 [TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E Mukherjee S; Sheng W; Michkov A; Sriarm K; Sun R; Dvorkin-Gheva A; Insel PA; Janssen LJ Am J Physiol Lung Cell Mol Physiol; 2019 May; 316(5):L810-L821. PubMed ID: 30758990 [TBL] [Abstract][Full Text] [Related]
16. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Ponticos M; Holmes AM; Shi-wen X; Leoni P; Khan K; Rajkumar VS; Hoyles RK; Bou-Gharios G; Black CM; Denton CP; Abraham DJ; Leask A; Lindahl GE Arthritis Rheum; 2009 Jul; 60(7):2142-55. PubMed ID: 19565505 [TBL] [Abstract][Full Text] [Related]
17. Bleomycin-induced E prostanoid receptor changes alter fibroblast responses to prostaglandin E2. Moore BB; Ballinger MN; White ES; Green ME; Herrygers AB; Wilke CA; Toews GB; Peters-Golden M J Immunol; 2005 May; 174(9):5644-9. PubMed ID: 15843564 [TBL] [Abstract][Full Text] [Related]
18. PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury. Osterholzer JJ; Christensen PJ; Lama V; Horowitz JC; Hattori N; Subbotina N; Cunningham A; Lin Y; Murdock BJ; Morey RE; Olszewski MA; Lawrence DA; Simon RH; Sisson TH J Pathol; 2012 Oct; 228(2):170-80. PubMed ID: 22262246 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4. Jiang D; Liang J; Campanella GS; Guo R; Yu S; Xie T; Liu N; Jung Y; Homer R; Meltzer EB; Li Y; Tager AM; Goetinck PF; Luster AD; Noble PW J Clin Invest; 2010 Jun; 120(6):2049-57. PubMed ID: 20484822 [TBL] [Abstract][Full Text] [Related]
20. Protease-activated receptor (PAR)-2 is required for PAR-1 signalling in pulmonary fibrosis. Lin C; von der Thüsen J; Daalhuisen J; ten Brink M; Crestani B; van der Poll T; Borensztajn K; Spek CA J Cell Mol Med; 2015 Jun; 19(6):1346-56. PubMed ID: 25689283 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]